
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Diazepam
Therapeutic Area : Neurology
Study Phase : Phase III
Recipient : Aquestive Therapeutics
Deal Size : $85.0 million
Deal Type : Agreement
Aquestive Therapeutics Receives First Milestone Payment from KYNMOBI™ Monetization
Details : The proceeds will help to execute on advancing company's key clinical and commercial initiatives, including the resubmission of its NDA for FDA approval of lead product Libervant™ Buccal Film and ongoing clinical trial for AQST-108.
Product Name : Libervant
Product Type : Controlled Substance
Upfront Cash : Undisclosed
November 23, 2020
Lead Product(s) : Diazepam
Therapeutic Area : Neurology
Highest Development Status : Phase III
Recipient : Aquestive Therapeutics
Deal Size : $85.0 million
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MP-101
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001
Details : MP-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Short Bowel Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 23, 2014
Lead Product(s) : MP-101
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MP-101
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MP-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Short Bowel Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 17, 2014
Lead Product(s) : MP-101
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
